Aegerion Pharmaceuticals, Inc. and QLT Inc. Complete Merger Transaction; QLT to Change Name to Novelion Therapeutics Inc.
November 29, 2016 12:09 ET
|
Aegerion Pharmaceuticals, Inc.; QLT Inc.
-- Transaction creates strong, diversified rare-disease focused portfolio-- Novelion Therapeutics completes concurrent financing of approximately $22 million -- Company to host conference call today...
Aegerion Pharmaceuticals’ JUXTAPID® (lomitapide) Capsules for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) Receives Pricing Authorization in Japan
November 17, 2016 16:15 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial Results
November 03, 2016 16:05 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals’ JUXTAPID® (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
September 28, 2016 16:05 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
September 24, 2016 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Aegerion Pharmaceuticals Appoints Remi Menes as Chief Commercial Officer
September 20, 2016 08:50 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Announces Second Quarter 2016 Financial Results
August 09, 2016 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
-- Company records $44.5 million in total net product sales ---- Company reiterates 2016 total net product sales guidance of between $130 and $150 million -- CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE...
Aegerion Pharmaceuticals Announces Cost Reduction Plans
July 20, 2016 16:02 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger
June 15, 2016 07:00 ET
|
Aegerion Pharmaceuticals, Inc.; QLT Inc.
--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
June 07, 2016 16:45 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...